Entera Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>EB</div>
ENTX -- USA Stock  

USD 1.28  0.05  4.07%

Entera Bio Total Debt is fairly stable at the moment as compared to the past year. Entera Bio reported Total Debt of 269,100 in 2019. Debt Non Current is likely to rise to about 112.7 K in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (11.4 M) in 2020. The basic goal of this article is to give investors our perspective on Entera for September. We will forecast Entera Bio value for investors.
Published over a month ago
View all stories for Entera Bio | View All Stories
Are Entera (NASDAQ:ENTX) investors starting to hold back?
Entera Bio has a beta of 1.2988. Let's try to break down what Entera's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Entera Bio will likely underperform. The beta indicator helps investors understand whether Entera Bio moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Entera deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Entera Bio. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Entera Bio


Watch out for price decline

Please consider monitoring Entera Bio on a daily bases if you are holding a position in it. Entera Bio is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Entera Bio stock to be traded above the $1 level to remain listed. If Entera Bio stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Entera Bio's Liquidity

Entera Bio financial leverage refers to using borrowed capital as a funding source to finance Entera Bio ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Entera Bio financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Entera Bio's total debt and its cash.

How Entera utilizes its cash?

To perform a cash flow analysis of Entera Bio, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Entera Bio is receiving and how much cash it distributes out in a given period. The Entera Bio cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Entera Bio Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Entera Bio reported Net Cash Flow from Operations of (8.92 Million) in 2019

A Deeper Perspective

Entera Bio is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Entera Bio implied risk.

Margin Breakdown

EBITDA Margin(48.26)
Gross Margin0.11
Profit Margin(49.35)

High level of complacency for Entera Bio after the current price slide

Coefficient of variation is down to 18897.43. It may suggest a possible volatility slide. Entera Bio is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Entera Bio implied risk.

Our Final Take On Entera Bio

While some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Entera Bio may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither purchase nor exit any shares of Entera Bio at this time. The Entera Bio risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Entera Bio.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Entera Bio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com